CLIA: 39D2085645
New York State has a separate and unique regulatory approval process for laboratory diagnostic testing. PeriRx is currently in the application process with our SaliMark™ OSCC test and is vigorously committed to pursuing this application approval.
Monthly Archives: May 2014
PeriRx LLC’s Robust Product Pipeline Includes Salivary Test for Sjogren’s Syndrome — a Common Symptom of Rheumatoid Arthritis
HAVERTOWN, PA–(Marketwired – May 28, 2014) – PeriRx LLC, a premier developer of breakthrough, non-invasive, salivary diagnostic technology, recently announced that it will be introducing a highly accurate and scientifically validated molecular biomarker test for the early detection of Sjögren’s Syndrome by the end of 2014.
Sjögren’s Syndrome is a systemic chronic inflammatory disorder in which the immune system attacks and damages the body’s moisture-producing glands. This causes dryness of the eyes and mouth and is associated with a number of oral and ocular complications. [Read more…]
Advanced salivary diagnostics’ impact on the reduction of oral cancer mortality rates
According to the Oral Cancer Foundation and the National Cancer Institute, about 43,000 people in the United States will be newly diagnosed with oral cancer in 2014. This includes those cancers that occur in the mouth itself, in the very back of the mouth known as the oropharynx, and on the exterior lip of the mouth [Read more…]